post of the day

featured

Latest stories

Recruitment we need more than a Trial Linked-In.

I was recently chastised for not working on the “real MS” what ever that is. But if I do come up with something for the “real MS” then it will need a trial, otherwise people are unlikely to accept the evidence. However, as I have said before “trials kill MS treatments” because sometime the people entering a trial is not optimised…So studies fail because...

Come-on people…if one company can do it after a decade, pull your finger out and get the answer for your new drugs, so I can understand what’s going on…..I can’t wait for a another decade:-(

OK this is a bit tounge in cheek, as I have known the answer foone -imod for some time, but many studies not sponsored by the manufacturer have talked about percentage effects and you have to deal with absolute numbers to grasp what is going on. This a current paper below is a company sponsored study and the results are easy to see, which is not always the case. These are reported here more than...

Does MS affect your baby?

There is little information out there on the effect of MS on a baby born to a mother with MS. Previous reports have noted a greater occurrence of pre-term delivery in mothers taking disease-modifying drugs (DMDs), as well as more C-sections and instrumental delivery. Anaemia and a greater occurrence of UTI has also been reported. In a review of 211 MS pregnancies in Italy comprising of foetal...

Switching to CD20 depletion

You asked about transitioning from fingolimod to anti-CD20 depleting antibodies one approach is to wait for the white blood cells to return. Here they do a quick switch. so you may find it interesting Transitioning From S1P Receptor Modulators to B Cell–Depleting Therapies in Multiple SclerosisClinical, Radiographic, and Laboratory Data William M. Rowles, Wan-Yu Hsu, Kira McPolin, et al...

On the way to targeting memoryy cells

Agonistic anti-CD27 antibody ameliorates EAE by suppressing IL-17 production. Vogel I, Acolty V, Keler T, Goriely S, Leo O, Moser M.Eur J Immunol. 2022. doi: 10.1002/eji.202149698. CD27/CD70 costimulation enhances T-cell survival, memory formation and Th1-cell differentiation and effector function. In addition to promoting Th1 responses, CD27 signalling has been shown to exert a...

Switching from Fingo

You asked about switching from fingolimod to another imod or anti-CD20. I am sorry I can’t give advice and maybe profK can tell us about the BartsMS standard, but it is important that the switch occurs to stop rebound occurring. Some people repopulate slowly after fingolimod but here is one persons view. It is open access so you can have a read. Barry B, Erwin AA, Stevens J, Tornatore C...

Pregnancy and the imods

There are 4 approved drugs that bind to the sphingosine-1-phosphate (S1P) receptor fingolimod is one another is siponimod and then there is ozanimod and recently ponesimod…What’s the difference? The receptor mediating the main effect on active MS is S1PR1 They all bind to this target and a few others. fingolimod hits S1P1,3,4,5, ponesimod is suggested to be S1P1-selective but it binds...

Domestic violence – a study reports from Iran

Domestic violence, often known as domestic abuse or intimate partner violence (IPV), is any pattern of behaviour aimed at establishing or maintaining dominance and authority over a partner. IPV is any kind of sexual, emotional, financial, or psychological harm or threat against another person. IPV is one of the most prevalent forms of violence against women worldwide [excerpt taken from this...

MS, Virginia Woolf and the Raverats

He was slowly dying from MS. His renewed friendship with the writer Virginia Woolf sustained him in the final years. More than one hundred years ago, the French artist Jacques Raverat and his wife Gwen, née Darwin, a wood engraver and granddaughter of the evolutionist, moved to southern France in hopes of slowing the progression of his multiple sclerosis. While living in Vence, away from the...

Translate

Categories

Recent Posts

Recent Comments

Archives